Clinical Trial Update: Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial of intravitreal ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy has completed and posted results in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Diabetic Retinopathy
• Vitreous Hemorrhage

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Jaeb Center for Health Research | Conditions: Vitreous Hemorrhage, Proliferative Diabetic Retinopathy | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2013-05-16